Liping Yang1,2, Yun Qiu3, Wenhua Ling3, Zhaomin Liu3, Lili Yang3, Changyi Wang4, Xiaolin Peng4, Li Wang4, Jianying Chen5. 1. Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, 74th ZhongShan Road II, GuangZhou, 510080, PR China. yanglp6@mail2.sysu.edu.cn. 2. Center for Chronic Disease Control, Nanshan, ShenZhen, PR China. yanglp6@mail2.sysu.edu.cn. 3. Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, 74th ZhongShan Road II, GuangZhou, 510080, PR China. 4. Center for Chronic Disease Control, Nanshan, ShenZhen, PR China. 5. GuangDong Province, BaiYun Hospital, YueXiu District, GuangZhou, PR China.
Abstract
BACKGROUND: Epidemiological studies have suggested that adipsin and visfatin are associated with the development of type 2 diabetes. This is the first study to investigate the effects of supplementation with purified anthocyanins on serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes. METHODS: A total of 160 participants with prediabetes or newly diagnosed diabetes (40-75 years old) were given 320 mg anthocyanins or placebo daily for 12 weeks in a randomized trial. Serum adipsin, serum visfatin, lipids and glycated hemoglobin A1c (HbA1c) were measured. The areas under the curve (AUCs) for glucose, insulin and C-peptide were determined before-and after-treatment by a standard 3-h 75 g oral glucose tolerance test (OGTT). RESULTS: Relatively significant increases in serum adipsin (net change 0.15 µg/mL [0.03, 0.27], p = 0.018) and decreases in visfatin (-3.5 ng/mL [-6.69, -0.31], p = 0.032) were observed between the anthocyanins and placebo groups. We also observed significant improvements in HbA1c (-0.11% [-0.22, -0.11], p = 0.033), apolipoprotein A-1 (apo A-1) (0.12 g/L [0.03, 0.21], p = 0.012) and apolipoprotein B (apo B) (-0.07 g/L [-0.14, -0.01], p = 0.033) in response to the anthocyanins intervention. CONCLUSION:Purified anthocyanins supplementation for 12 weeks increased serum adipsin and decreased serum visfatin in patients with prediabetes or newly diagnosed diabetes. Trial registration ClinicalTrials.gov, identifier: NCT02689765.
RCT Entities:
BACKGROUND: Epidemiological studies have suggested that adipsin and visfatin are associated with the development of type 2 diabetes. This is the first study to investigate the effects of supplementation with purified anthocyanins on serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes. METHODS: A total of 160 participants with prediabetes or newly diagnosed diabetes (40-75 years old) were given 320 mg anthocyanins or placebo daily for 12 weeks in a randomized trial. Serum adipsin, serum visfatin, lipids and glycated hemoglobin A1c (HbA1c) were measured. The areas under the curve (AUCs) for glucose, insulin and C-peptide were determined before-and after-treatment by a standard 3-h 75 g oral glucose tolerance test (OGTT). RESULTS: Relatively significant increases in serum adipsin (net change 0.15 µg/mL [0.03, 0.27], p = 0.018) and decreases in visfatin (-3.5 ng/mL [-6.69, -0.31], p = 0.032) were observed between the anthocyanins and placebo groups. We also observed significant improvements in HbA1c (-0.11% [-0.22, -0.11], p = 0.033), apolipoprotein A-1 (apo A-1) (0.12 g/L [0.03, 0.21], p = 0.012) and apolipoprotein B (apo B) (-0.07 g/L [-0.14, -0.01], p = 0.033) in response to the anthocyanins intervention. CONCLUSION: Purified anthocyanins supplementation for 12 weeks increased serum adipsin and decreased serum visfatin in patients with prediabetes or newly diagnosed diabetes. Trial registration ClinicalTrials.gov, identifier: NCT02689765.
Authors: Jaakko Mursu; Jyrki K Virtanen; Tomi-Pekka Tuomainen; Tarja Nurmi; Sari Voutilainen Journal: Am J Clin Nutr Date: 2013-11-20 Impact factor: 7.045
Authors: James C Lo; Sanda Ljubicic; Barbara Leibiger; Matthias Kern; Ingo B Leibiger; Tilo Moede; Molly E Kelly; Diti Chatterjee Bhowmick; Incoronata Murano; Paul Cohen; Alexander S Banks; Melin J Khandekar; Arne Dietrich; Jeffrey S Flier; Saverio Cinti; Matthias Blüher; Nika N Danial; Per-Olof Berggren; Bruce M Spiegelman Journal: Cell Date: 2014-07-03 Impact factor: 41.582
Authors: Pouya Saeedi; Inga Petersohn; Paraskevi Salpea; Belma Malanda; Suvi Karuranga; Nigel Unwin; Stephen Colagiuri; Leonor Guariguata; Ayesha A Motala; Katherine Ogurtsova; Jonathan E Shaw; Dominic Bright; Rhys Williams Journal: Diabetes Res Clin Pract Date: 2019-09-10 Impact factor: 5.602
Authors: Nicole M Wedick; An Pan; Aedín Cassidy; Eric B Rimm; Laura Sampson; Bernard Rosner; Walter Willett; Frank B Hu; Qi Sun; Rob M van Dam Journal: Am J Clin Nutr Date: 2012-02-22 Impact factor: 7.045
Authors: Marta Olivera-Santa Catalina; Pedro C Redondo; Maria P Granados; Carlos Cantonero; Jose Sanchez-Collado; Letizia Albarran; Jose J Lopez Journal: Curr Med Chem Date: 2019 Impact factor: 4.530